Amyotrophic Lateral Sclerosis

ALS clinical trials are one of Julius Clinical’s focus areas, and we are dedicated to aiding in the discovery of truly life-changing treatments for patients.

The incidence rate of ALS is growing, making the need for treatments increasingly urgent. In every ALS clinical trial, we apply the full breadth of our scientific expertise, operational insights, and the support of our partner, TRICALS, which has a strong European network of ALS-specific sites.

Meet our scientific leader for ALS clinical trials

Our scientific leader in ALS is Prof. dr. Leonard van den Berg, professor of neurology at the University Medical Centre (UMC) Utrecht and director of ALS Centrum Nederland (the Dutch ALS Centre). He has vast experience in global ALS trials, established the prominent ALS site network TRICALS, and chairs the European Network to Cure ALS.

Brain Clinical is our proprietary network for CNS studies, providing highly experienced researchers for CNS clinical trials.


We are proud to partner with TRICALS, the largest European research initiative to find a cure and effective treatments for ALS. Our partnership with TRICALS provides innovative trial design and oversight capabilities combined with seasoned operational efficiency. With their help, we provide excellent patient recruitment and retention to support optimal execution for your ALS study.

Read more

Whether your project is a Phase I– III clinical trial, an investigator-initiated trial, an observational study or includes Real World Data; we have many years of experience in clinical trials in the field of ALS and provide you with a tailor-made solution that suits your needs.

Phase II European

Ongoing

175 patients | 8 countries | 25 sites

A Phase II, Multicenter, Randomized, Double-Blind Study Evaluating Safety and Efficacy in Patients with Amyotrophic Lateral Sclerosis

Phase III Global

Ongoing

600 patients | 12 countries | 75 sites

Multicenter trial for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis

Phase III European

Ongoing

300 patients | 9 countries | 31 sites

A multicenter study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis.


Julius Clinical’s expert ALS team

With our broad expertise gained through years of managing ALS clinical trials, Julius Clinical has the right people to give clients the best possible trial experience. Our in-house experts have skills and devotion that make a difference in ALS studies.

Lieza exalto

Related webinars

ALS resources

Explore our ALS trial capabilities, case studies, and other resources.

Download

"*" indicates required fields

*

Request for proposal

"*" indicates required fields

*
This field is for validation purposes and should be left unchanged.

Share

Twitter Facebook LinkedIn